以前にエミシズマブによる予防治療を受けた重度の血友病患者の出血を防ぐための薬(フィツシラン)を試験する研究
阻害剤の有無にかかわらず、重度血友病Aの18歳以上の男性参加者を対象に、エミシズマブからフィツシランへの予防投与切り替えの安全性と忍容性を調査する非盲検単群治療研究
This is an exploratory, single group, Phase 4, study to assess treatment with fitusiran prophylaxis after switching from emicizumab prophylaxis.
This study aims to evaluate the safety and tolerability of switching to fitusiran after a transition period from the last dose of emicizumab. The study will be conducted in male participants with severe hemophilia A, with or without inhibitors, aged ≥12 years, who were previously receiving emicizumab prophylaxis.
Study details include:
-
The study duration will be up to approximately 28 months:
- There will be an approximately 2-month screening period.
- There will be an approximately 2-month period before fitusiran treatment starts (pre-fitusiran treatment period)
- The fitusiran treatment duration will be up to 18-months (fitusiran treatment period)
- The antithrombin (AT) follow-up (FU) period will be approximately 6 months after the last dose of fitusiran (during which the AT activity level will be monitored at approximately monthly intervals following the final fitusiran dose until AT activity levels return to at least 60%).
-
The study site visits are scheduled at monthly/ every 2 months intervals of 28 days (4 weeks) / 56 days (8 weeks), respectively, during the fitusiran treatment period.
調査の概要
状態
条件
研究の種類
入学 (推定)
段階
- フェーズ 4
連絡先と場所
研究連絡先
- 名前:Trial Transparency email recommended (Toll free for US & Canada)
- 電話番号:option 6 800-633-1610
- メール:Contact-US@sanofi.com
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Male participants must be ≥12 years of age inclusive, at the time of signing the informed consent
-
Diagnosis of severe congenital hemophilia A (FVIII < 1%) as evidenced by a central laboratory measurement at screening or documented medical record evidence.
- Inhibitor titer of ≥0.6 BU/mL at Screening, or
- Inhibitor titer of <0.6 BU/mL at Screening with medical record evidence of 2 consecutive titers ≥0.6 BU/mL, or
- Inhibitor titer of <0.6 BU/mL at Screening with medical record evidence of anamnestic response.
-
Participants who are currently on the full labeled dose of emicizumab prophylaxis, irrespective of inhibitor/non-inhibitor status.
-
Signed informed consent/assent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
- Known coexisting bleeding disorders
- History of antiphospholipid antibody syndrome.
- History of arterial or venous thromboembolism, atrial fibrillation, significant valvular disease, myocardial infarction, angina, transient ischemic attack, or stroke. Participants who have experienced thrombosis associated with indwelling venous access may be enrolled.
- Presence of clinically significant liver disease
- Current or prior participation in a fitusiran trial
- Current or prior participation in a gene therapy trial
- AT activity <60% at Screening, as determined by central laboratory measurement
- Coexisting thrombophilic disorder - Hepatitis C virus antibody positive, except participants who have negative Hepatitis C viral load and no evidence of cirrhosis
- Presence of acute hepatitis, ie, hepatitis A, hepatitis E.
- Presence of acute or chronic hepatitis B infection
- Known to be HIV positive with CD4 count <200 cells/μL.
- Reduced renal function
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:fitusiran
The pre-fitusiran treatment period is defined as the transition period up to the first fitusiran administration. Participants will receive on demand or prophylactic treatment with intravenous clotting factor concentrates (IV CFCs) or bypassing agents (BPAs) from Month-2 until Day 1. Fitusiran treatment period: Participants will receive subcutaneous (SC) fitusiran prophylaxis once every 2 months (Q2M) or once monthly (QM) from Day 1 until Month18. Participants may receive IV antithrombin concentrate (ATIIIC) upon investigator's judgement. AT FU period: Participants will be followed up until AT activity levels recover to at least 60% (per central laboratory). In case of bleeding events participants will receive IV CFCs or BPAs. Participants may receive IV ATIIIC upon investigator's judgement. |
Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous (SC) injection
他の名前:
Pharmaceutical form: Solution for injection-Route of administration: Intravenous (IV) injection Pharmaceutical form:Solution for injection-Route of administration:Intravenous (IV) injection Pharmaceutical form:Solution for injection-Route of administration:SC injection |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of participants with Adverse events (AEs) during the fitusiran treatment
時間枠:From Day 1 up to Month 4
|
Incidence, severity, and seriousness, of AEs occurred during fitusiran treatment period will be reported |
From Day 1 up to Month 4
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
The peak thrombin generation (TG) - pre fitusiran treatment
時間枠:From Month -2 up to Day 1
|
Central laboratory assessments (peak TG) will be reported for pre-fitusiran period |
From Month -2 up to Day 1
|
|
The peak TG during fitusiran treatment
時間枠:From Day 1 up to Month 4
|
Central laboratory assessments (peak TG) will be reported for fitusiran treatment period |
From Day 1 up to Month 4
|
|
The antithrombin (AT) levels during pre-fitusiran treatment
時間枠:From Month -2 up to Day 1
|
Central laboratory assessments (AT) will be reported for pre-fitusiran treatment period |
From Month -2 up to Day 1
|
|
The AT levels during fitusiran prophylaxis
時間枠:From Day 1 up to Month 4
|
Central laboratory assessments (AT) will be reported for fitusiran treatment |
From Day 1 up to Month 4
|
|
Emicizumab concentrations in plasma
時間枠:Up to Month 4 of fitusiran treatment
|
Emicizumab concentrations in plasma will be reported |
Up to Month 4 of fitusiran treatment
|
|
Number of participants with AEs from Day 1 to Month 18 of fitusiran treatment
時間枠:From Day 1 up to Month 18
|
Incidence, severity, and seriousness of AEs will be reported |
From Day 1 up to Month 18
|
|
Change in participants' overall treatment satisfaction during the fitusiran treatment period assessed via the Treatment Satisfaction Questionnaire for Medication (TSQM-9) domain scores
時間枠:From approximately Month -2 to Month 19 [end of study (EoS) visit]
|
The three domains of effectiveness, convenience, and global satisfaction will be reported |
From approximately Month -2 to Month 19 [end of study (EoS) visit]
|
|
Participants' treatment preferences (via the Preference Questionnaire)
時間枠:At Month 12
|
The Preference questionnaire Data will be reported |
At Month 12
|
|
Change in adult participants' pain intensity during the fitusiran treatment period over time
時間枠:From approximately Month - 2 to Month 19 (EoS) visit
|
The PROMIS (Patient-Reported Outcomes Measurement Information System) Pain Intensity 3a v2.0 consists of three items measuring the worst, average, and current intensity of pain with a recall period of 7 days. Each question has five response options ranging from one ('no pain') to five ('very severe'). Adult participants (age ≥ 18 years) will self-complete the PROMIS Pain Intensity 3a v2.0 questionnaire. |
From approximately Month - 2 to Month 19 (EoS) visit
|
|
Change in adolescent participants' pain intensity during the fitusiran treatment period over time
時間枠:From approximately Month - 2 to Month 19 (EoS) visit
|
The PROMIS Pediatric Numeric Rating Scale v.1.0 - Pain Intensity 1a consists of one item measuring the average intensity of pain with a recall period of 7 days. The question has ten response options ranging from one ('no pain') to ten ('worst pain'). Adolescent participants (age ≥12 years and <17 years) will self-complete the PROMIS Pediatric Pain Intensity 1a v.1.0. |
From approximately Month - 2 to Month 19 (EoS) visit
|
|
Change in participants' physical functioning and physical activity during the fitusiran treatment period (via the International Physical Activity Questionnaire [IPAQ]) over time
時間枠:From approximately Month - 2 to Month 19 (EoS) visit
|
Participants' physical functioning and physical activity data during the fitusiran treatment period will be collected via the International Physical Activity Questionnaire and reported |
From approximately Month - 2 to Month 19 (EoS) visit
|
|
Change in participants' joint health (via the Hemophilia Joint Health Score [HJHS]) during the fitusiran treatment period over time
時間枠:From approximately Month - 2 to Month 19 (EoS) visit
|
HJHS during the fitusiran treatment period will be reported |
From approximately Month - 2 to Month 19 (EoS) visit
|
|
Annualized Bleeding Rate (ABR) while receiving fitusiran prophylaxis
時間枠:From Month 4 up to Month 18 (14-month extension period)
|
The frequency of treated bleeding episodes will be reported |
From Month 4 up to Month 18 (14-month extension period)
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Clinical Sciences & Operations、Sanofi
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- SFY17741
- 2022-502414-84 (レジストリ識別子:CTIS)
- U1111-1280-7227 (レジストリ識別子:ICTRP)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。